help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Binder, G.
Right arrow Articles by Ranke, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Binder, G.
Right arrow Articles by Ranke, M. B.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 1 245-249
Copyright © 2000 by The Endocrine Society


Original Studies

Identification of Short Stature Caused by SHOX Defects and Therapeutic Effect of Recombinant Human Growth Hormone

G. Binder1, C. P. Schwarze and M. B. Ranke

University Children’s Hospital and Growth Research Center, University Tübingen, 72076 Tübingen, Germany

Address correspondence and requests for reprints to: Dr. Gerhard Binder, University Children’s Hospital, Hoppe-Seyler-Str.1, 72076 Tübingen, Germany.

Point mutations or complete deletions of SHOX, the short-stature homeobox-containing gene on the pseudoautosomal region of the sex chromosomes (Xp22 and Yp11.3), were recently reported in one family with idiopathic short stature and in several families with Leri-Weill syndrome (dyschondrosteosis). The missing SHOX is also thought to attribute to the growth failure in Turner syndrome. For testing the frequency of defects of SHOX in unexplained growth failure and recombinant human GH (rhGH) as a possible growth-promoting agent, we selected 68 children with idiopathic short stature. These probands had heights below -2.0 SD score for age, normal target heights, no significant bone age retardations, no endocrine abnormalities, no skeletal diseases, and no other organic diseases. No mutations were detected by single-strand conformational polymorphism analysis of the PCR-amplified SHOX. The analysis of three microsatellite DNA markers of the pseudoautosomal region, including one located on the 5' untranslated region of SHOX-exon 1, identified a 15-yr-old girl who carried a mutation in the form of a complete SHOX deletion. This girl who had a normal karyotype presented with mild mesomelic shortening of the forearms and lower legs. We treated two children with short stature on the basis of a SHOX point mutation (C674T) with rhGH at a dose of 1.0 IU/kg body weight·week in accordance with the regimen used in Turner syndrome. During the first 12 months of treatment, these two children (5.9- and 8.4-yr-old) showed an excellent growth spurt with a growth rate of 9.5 and 9.4 cm/yr, respectively. Growth of the lower extremities was weaker than in the trunk and arms. Our data suggest that short stature due to SHOX deletions is not a rare entity. Growth-promoting therapy with rhGH was effective with regard to height gain, but a tendency to disproportionate growth was apparent. In cases of unexplained growth failure, especially if associated with any mild skeletal disproportions, genetic analysis of SHOX should be considered.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
G. Binder, A. Renz, A. Martinez, A. Keselman, V. Hesse, S. W. Riedl, G. Hausler, S. Fricke-Otto, H. Frisch, J. J. Heinrich, et al.
SHOX Haploinsufficiency and Leri-Weill Dyschondrosteosis: Prevalence and Growth Failure in Relation to Mutation, Sex, and Degree of Wrist Deformity
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4403 - 4408.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Binder, M. B. Ranke, and D. D. Martin
Auxology Is a Valuable Instrument for the Clinical Diagnosis of SHOX Haploinsufficiency in School-Age Children with Unexplained Short Stature
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4891 - 4896.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
L Stuppia, G Calabrese, V Gatta, S Pintor, E Morizio, D Fantasia, P Guanciali Franchi, M M Rinaldi, G Scarano, D Concolino, et al.
SHOX mutations detected by FISH and direct sequencing in patients with short stature
J. Med. Genet., February 1, 2003; 40(2): e11 - 11.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. A. Rappold, M. Fukami, B. Niesler, S. Schiller, W. Zumkeller, M. Bettendorf, U. Heinrich, E. Vlachopapadoupoulou, T. Reinehr, K. Onigata, et al.
Deletions of the Homeobox Gene SHOX (Short Stature Homeobox) Are an Important Cause of Growth Failure in Children with Short Stature
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1402 - 1406.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. G. Rosenfeld
EDITORIAL: A SHOX to the System
J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5672 - 5673.
[Full Text] [PDF]


Home page
J. Med. Genet.Home page
T. Ogata, N. Matsuo, and G. Nishimura
SHOX haploinsufficiency and overdosage: impact of gonadal function status
J. Med. Genet., January 1, 2001; 38(1): 1 - 6.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
X.-L. Wang, M. Bassett, Y. Zhang, S. Yin, C. Clyne, P. C. White, and W. E. Rainey
Transcriptional Regulation of Human 11{beta}-Hydroxylase (hCYP11B1)
Endocrinology, October 1, 2000; 141(10): 3587 - 3594.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society